Biogen (BIIB) reported stronger-than-expected Q3 results, topping both earnings and revenue estimates. The company also raised its FY2021 guidance above analyst expectations.
Biogen (BIIB) recently inked a license and partnership agreement with InnoCare Pharma Limited. Biogen will gain exclusive rights to Orelabrutinib for the worldwide …
According to a report published by Reuters, the U.S.
The global biotechnology company Biogen, Inc. (BIIB) and Eisai, Co.
Biogen (BIIB) has entered into a research collaboration with Capsigen Inc. to develop novel adeno-associated virus (AAV) capsids.
Biogen Inc’s TECFIDERA has received approval from the National Medical Products Administration (NMPA) in China for treating relapsing multiple sclerosis (MS). This approval …
Biogen’s shares dropped 5.2% on Feb.
Biogen shares were up by 5.5% on Jan.
Shares of Biogen exploded 44% after staff at the US Food and Drug Administration (FDA) concluded in a review that there was “substantial …
The COVID-19 pandemic has led to a wake-up call for governments, as they realize the significant investment required by the healthcare sector. Billions …